UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1377-4
Program Prior Authorization/Notification
Medication Tavneos® (avacopan)
P&T Approval Date 1/2022, 1/2023, 1/2024, 1/2025
Effective Date 4/1/2025
1. Background:
Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist indicated as an adjunctive
treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-
associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis
[MPA]) in combination with standard therapy including glucocorticoids. Tavneos does not
eliminate glucocorticoid use.
2. Coverage Criteriaa:
A. Anti-Neutrophil Cytoplasmic Autoantibody (ANCA) - Associated Vasculitis
1. Initial Authorization
a. Tavneos will be approved based all of the following criteria:
(1) Diagnosis of severe active ANCA-associated vasculitis
-AND-
(2) Disease is one of the following types:
(a) Granulomatosis with polyangiitis (GPA)
(b) Microscopic polyangiitis (MPA)
-AND-
(3) Used as adjunctive treatment in combination with standard therapy (e.g., prednisone,
azathioprine, mycophenolate, methotrexate, rituximab, cyclophosphamide)
Authorization will be issued for 6 months.
2. Reauthorization
a. Tavneos will be approved based on both of the following criteria:
(1) Patient does not show evidence of progressive disease while on Tavneos therapy
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
(2) Used as adjunctive treatment in combination with standard therapy (e.g., prednisone,
azathioprine, mycophenolate, methotrexate, rituximab, cyclophosphamide)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
• Medical Necessity may be in place.
4. References:
1. Tavneos [package insert]. Cincinnati, OH: Thermo Fisher Scientific; June 2024.
Program Prior Authorization/Notification – Tavneos® (avacopan)
Change Control
12/2021 New program
1/2023 Annual review with no change to coverage criteria. Added state
mandate footnote.
1/2024 Annual review with no changes.
1/2025 Annual review with no changes to coverage criteria. Updated reference.
© 2025 UnitedHealthcare Services, Inc.
2